Kane Biotech Inc V.KNE

New Press Release - Kane Biotech Announces Third Quarter 2024 Financial Results

Company Records First Commercial Sale of revyve™ Wound Gel WINNIPEG, Manitoba, Nov. 28, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) today announces its third quarter 2024 financial results.Third Quarter 2024 Financial Highlights ...read article.

[francoisl13]

Well... 3rd QTR numbers are out and they look pretty decent to me especially on the expenses front. If you take into account everything that happened during the past QTR, it is pretty amazing to see that they've been able to keep good control over the expenses. The service fees are hign so we can imagine that this revenue will disappear sooner than later but at the same time Revyve sales are

[KevinOleary]

He also said there could be another multinational collaboration, which would be in addition to the one he announced in the last month or so.

[francoisl13]

Correct and if I understand well, this upcoming collaboration will, again, be for DispersinB. He also made a comment, and this is not the first time he does, about the fact that other major players in the wound care area are showing interest for DispersinB.  Things to look for in the weeks before the Holidays (from Kane's latest presentation and video); 1. Pot'l financing... 2. Start